Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women.

Front Oncol · 2021 · PMC8477635 · PMID 34595110

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A numerically greater benefit in 5-year DFS rates was observed for letrozole plus OFS versus tamoxifen plus OFS although the difference did not reach statistical significance ( 54 ) ( Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.